Sign In
Buy NVCT
$9.31
-0.200 (-2.10%)
At Close: Jun 03, 2026
Wall Street Analysts Think Nuvectis Pharma (NVCT) Could Surge 57%: Read This Before Placing a Bet
10:56am, Monday, 25'th May 2026
The mean of analysts' price targets for Nuvectis Pharma (NVCT) points to a 57% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among an
Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
07:30am, Thursday, 14'th May 2026
Fort Lee, NJ, May 14, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative p
Wall Street Analysts Believe Nuvectis Pharma (NVCT) Could Rally 62.5%: Here's is How to Trade
10:55am, Thursday, 07'th May 2026
The average of price targets set by Wall Street analysts indicates a potential upside of 62.5% in Nuvectis Pharma (NVCT). While the effectiveness of this highly sought-after metric is questionable, th
Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights
07:30am, Tuesday, 05'th May 2026
FORT LEE, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting
08:00am, Tuesday, 31'st Mar 2026
Fort Lee, NJ, March 31, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative
Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights
07:30am, Wednesday, 11'th Feb 2026
FORT LEE, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovativ
Nuvectis Pharma (NASDAQ:NVCT) Trading Up 5.8% – Should You Buy?
03:33am, Thursday, 22'nd Jan 2026
Nuvectis Pharma, Inc. (NASDAQ: NVCT - Get Free Report) shot up 5.8% on Wednesday. The company traded as high as $8.63 and last traded at $8.58. 58,015 shares were traded during mid-day trading, a decl
Nuvectis Pharma (NASDAQ:NVCT) Stock Price Up 0.5% – Here’s Why
02:08am, Saturday, 27'th Dec 2025
Nuvectis Pharma, Inc. (NASDAQ: NVCT - Get Free Report)'s stock price rose 0.5% on Friday. The company traded as high as $7.91 and last traded at $7.75. Approximately 22,642 shares changed hands during
Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC
07:00am, Wednesday, 17'th Dec 2025
The study is designed to evaluate the safety and clinical activity of NXP900 in combination with osimertinib in patients with epidermal growth factor receptor mutated (EGFR mut+) non-small cell lung c
Fort Lee, NJ, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT, the “Company”), a clinical stage biopharmaceutical company focused on the development of innovative precision m
CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights
08:15am, Tuesday, 04'th Nov 2025
FORT LEE, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline on November 4, 2025 at 07:30 ET by Nuvectis Pharma, Inc. (NASDAQ: NVCT), the tables were not included. The
Fort Lee, NJ, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the tr
Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference
07:30am, Thursday, 04'th Sep 2025
Fort Lee, NJ, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative
Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900
04:30pm, Monday, 11'th Aug 2025
The Phase 1b program is designed to evaluate the clinical activity of NXP900 as a single agent in patients with advanced solid tumors whose cancers harbor specific genetic alterations, and in combinat
Nuvectis (NVCT) Q2 Loss Widens 43%
09:57pm, Tuesday, 05'th Aug 2025
Nuvectis (NVCT) Q2 Loss Widens 43%
